{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:39:30Z","timestamp":1791819570770,"version":"4.3.4"},"posted":{"date-parts":[[2025,5,3]]},"group-title":"Neurology","reference-count":58,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T00:00:00Z","timestamp":1746230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.medrxiv.org\/about\/FAQ#license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,5,3]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Progression independent of relapses (PIRA) is a major therapeutic challenge in multiple sclerosis (MS). Nasal anti-CD3 treats animal models of progressive MS by inducing regulatory T cells (Tregs) that suppress central nervous system (CNS) inflammation and lessen clinical disease.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Ten patients with non-active secondary progressive MS (naSPMS) that continued to progress on B cell therapy were treated with nasal anti-CD3 (foralumab) for a minimum of six months in an open label study. Safety monitoring included otolaryngology evaluation and neurologic assessments including Expanded Disability Status Scale (EDSS), Multiple Sclerosis Functional Composite (MSFC-4), Modified Fatigue Impact Scale (MFIS), California Verbal Learning Test (CVLT-II) and Low Contract Visual Acuity (LCVA). MRI and microglial translocator protein (TSPO)-PET imaging with [F-18]PBR06 were conducted. Serum and cerebrospinal fluid (CSF) proteomic biomarkers and single cell RNA sequencing of blood was performed to evaluate foralumab-induced immunomodulation. The endpoints of our study were safety, clinical effects, microglial signal and immune measures.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All patients stabilized on EDSS scores and three of four patients treated continuously for 12 months had improvement on EDSS. Six of 10 patients had improvement in fatigue on the MFIS scale. There were no treatment-related serious adverse events (SAEs) or severe AEs and no new T2 lesions were observed on MRI. There was a reduction in TSPO-PET signal over six months (p&lt;0.05). Changes in peripheral blood gene expression occurred as early as three months and affected antigen presentation, interferon responses and regulatory pathways in multiple cell types including FoxP3+ Tregs, CD4+ Tcm cells, CD8+ Tem cells, CD14+ and CD16+ monocytes and B cells. TGF\u03b2 expression was increased across cell multiple subsets.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Interpretation<\/jats:title>\n                  <jats:p>These findings identify a novel, non-toxic immune based therapy for the treatment for PIRA that acts by the induction of a regulatory immune responses and dampens microglial inflammation. Double blind placebo-controlled trials are warranted to explore nasal foralumab for the treatment of naSPMS.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.04.30.25326602","type":"posted-content","created":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T01:55:15Z","timestamp":1746323715000},"source":"Crossref","is-referenced-by-count":4,"title":["Nasal foralumab treatment of PIRA induces regulatory immunity, dampens microglial activation and stabilizes clinical progression in non-active secondary progressive MS"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9897-4422","authenticated-orcid":false,"given":"Tanuja","family":"Chitnis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Singhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2896-8369","authenticated-orcid":false,"given":"Jonathan","family":"Zurawski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2605-8505","authenticated-orcid":false,"given":"Taylor J.","family":"Saraceno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niveditha","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Cain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenna","family":"LaBarre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devin","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regan W.","family":"Bergmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice Z.","family":"Maxfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Cicero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shipra","family":"Dubey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Vaquerano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Hansel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shrishti","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrishikesh","family":"Lokhande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moogeh","family":"Baharnoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Madill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manali","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Rodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William A.","family":"Clementi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard L.","family":"Weiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"issue":"9","key":"2025050613201881000_2025.04.30.25326602v1.1","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials","volume":"77","year":"2020","journal-title":"JAMA Neurol"},{"key":"2025050613201881000_2025.04.30.25326602v1.2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac016"},{"key":"2025050613201881000_2025.04.30.25326602v1.3","doi-asserted-by":"publisher","DOI":"10.1172\/jci90609"},{"key":"2025050613201881000_2025.04.30.25326602v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(22)00289-7"},{"key":"2025050613201881000_2025.04.30.25326602v1.5","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh641"},{"issue":"2","key":"2025050613201881000_2025.04.30.25326602v1.6","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41582-024-01046-7","article-title":"Immune mechanisms and shared immune targets in neurodegenerative diseases","volume":"21","year":"2025","journal-title":"Nat Rev Neurol"},{"key":"2025050613201881000_2025.04.30.25326602v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-024-01077-7"},{"key":"2025050613201881000_2025.04.30.25326602v1.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-065X.2011.01017.x"},{"key":"2025050613201881000_2025.04.30.25326602v1.9","doi-asserted-by":"publisher","DOI":"10.1615\/CritRevImmunol.2018026181"},{"key":"2025050613201881000_2025.04.30.25326602v1.10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.181.9.6038"},{"key":"2025050613201881000_2025.04.30.25326602v1.11","doi-asserted-by":"publisher","DOI":"10.1038\/nm1408"},{"issue":"8","key":"2025050613201881000_2025.04.30.25326602v1.12","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/imt-2016-0049","article-title":"Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside","volume":"8","year":"2016","journal-title":"Immunotherapy"},{"key":"2025050613201881000_2025.04.30.25326602v1.13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308743"},{"key":"2025050613201881000_2025.04.30.25326602v1.14","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww113"},{"key":"2025050613201881000_2025.04.30.25326602v1.15","doi-asserted-by":"crossref","first-page":"956907","DOI":"10.3389\/fimmu.2022.956907","article-title":"Nasal administration of anti-CD3 monoclonal antibody modulates effector CD8+ T cell function and induces a regulatory response in T cells in human subjects","volume":"13","year":"2022","journal-title":"Front Immunol"},{"key":"2025050613201881000_2025.04.30.25326602v1.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05379-z"},{"issue":"11","key":"2025050613201881000_2025.04.30.25326602v1.17","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/S1474-4422(20)30346-X","article-title":"PET imaging of neuroinflammation in neurological disorders","volume":"19","year":"2020","journal-title":"Lancet Neurol"},{"key":"2025050613201881000_2025.04.30.25326602v1.18","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awy296"},{"key":"2025050613201881000_2025.04.30.25326602v1.19","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-40937-z"},{"key":"2025050613201881000_2025.04.30.25326602v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.08.008"},{"issue":"5","key":"2025050613201881000_2025.04.30.25326602v1.21","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1055\/s-0037-1608715","article-title":"TSPO-PET Imaging to Assess Cerebral Microglial Activation in Multiple Sclerosis","volume":"37","year":"2017","journal-title":"Semin Neurol"},{"key":"2025050613201881000_2025.04.30.25326602v1.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00537-1"},{"key":"2025050613201881000_2025.04.30.25326602v1.23","doi-asserted-by":"crossref","unstructured":"Singhal T , Cicero S , Pan H , et al. Regional microglial activation in the substantia nigra is linked with fatigue in MS. Neurol Neuroimmunol Neuroinflamm. 2020 Sep 3;7(5).","DOI":"10.1212\/NXI.0000000000000854"},{"key":"2025050613201881000_2025.04.30.25326602v1.24","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa275"},{"key":"2025050613201881000_2025.04.30.25326602v1.25","doi-asserted-by":"crossref","first-page":"104755","DOI":"10.1016\/j.msard.2023.104755","article-title":"Early prognosticators of later TSPO-PET-measurable microglial activation in multiple sclerosis","volume":"75","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"2025050613201881000_2025.04.30.25326602v1.26","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000587"},{"key":"2025050613201881000_2025.04.30.25326602v1.27","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.131698"},{"issue":"2","key":"2025050613201881000_2025.04.30.25326602v1.28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/RLU.0000000000003398","article-title":"Widespread Glial Activation in Primary Progressive Multiple Sclerosis Revealed by 18F-PBR06 PET: A Clinically Feasible, Individualized Approach","volume":"46","year":"2021","journal-title":"Clin Nucl Med"},{"issue":"6","key":"2025050613201881000_2025.04.30.25326602v1.29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/RLU.0000000000005201","article-title":"Glial Activity Load on PET Reveals Persistent \u201cSmoldering\u201d Inflammation in MS Despite Disease-Modifying Treatment: 18 F-PBR06 Study","volume":"49","year":"2024","journal-title":"Clin Nucl Med"},{"key":"2025050613201881000_2025.04.30.25326602v1.30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007371"},{"issue":"7","key":"2025050613201881000_2025.04.30.25326602v1.31","first-page":"1238","article-title":"A diagnostic approach in Alzheimer\u2019s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET","volume":"36","year":"1995","journal-title":"J Nucl Med"},{"key":"2025050613201881000_2025.04.30.25326602v1.32","doi-asserted-by":"publisher","DOI":"10.1111\/jon.12491"},{"key":"2025050613201881000_2025.04.30.25326602v1.33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jns.2019.04.023","article-title":"The impact of cervical spinal cord atrophy on quality of life in multiple sclerosis","volume":"403","year":"2019","journal-title":"J Neurol Sci"},{"key":"2025050613201881000_2025.04.30.25326602v1.34","doi-asserted-by":"crossref","unstructured":"Barro C , Healy BC , Liu Y , et al. Serum GFAP and NfL Levels Differentiate Subsequent Progression and Disease Activity in Patients With Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023 Jan;10(1).","DOI":"10.1212\/NXI.0000000000200052"},{"key":"2025050613201881000_2025.04.30.25326602v1.35","doi-asserted-by":"publisher","DOI":"10.1038\/S41587-023-01767-Y"},{"key":"2025050613201881000_2025.04.30.25326602v1.36","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.3192"},{"key":"2025050613201881000_2025.04.30.25326602v1.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2019.05.031"},{"key":"2025050613201881000_2025.04.30.25326602v1.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-019-0619-0"},{"key":"2025050613201881000_2025.04.30.25326602v1.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-020-0820-1"},{"key":"2025050613201881000_2025.04.30.25326602v1.40","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELL.2021.04.048"},{"key":"2025050613201881000_2025.04.30.25326602v1.41","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0550-8"},{"key":"2025050613201881000_2025.04.30.25326602v1.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2015.12.004"},{"key":"2025050613201881000_2025.04.30.25326602v1.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2019.07.028"},{"key":"2025050613201881000_2025.04.30.25326602v1.44","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02532-6"},{"key":"2025050613201881000_2025.04.30.25326602v1.45","unstructured":"Cicero S , Hansel C , Dubey S , et al. Cortical Microglial Activation Mediates the Relationship Between Fatigue and Progression Independent of Relapse Activity (PIRA) in Multiple Sclerosis: A 4.5-year Longitudinal Study. Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS); Februray 27, 2025 to March 1, 2025; West Palm Beach, Florida2025."},{"key":"2025050613201881000_2025.04.30.25326602v1.46","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000574"},{"key":"2025050613201881000_2025.04.30.25326602v1.47","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.116.183020"},{"key":"2025050613201881000_2025.04.30.25326602v1.48","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-011-6337-x"},{"key":"2025050613201881000_2025.04.30.25326602v1.49","unstructured":"49. Singhal T , Cicero S , Gale S , et al. Dampening of microglial activation with nasal foralumab administration in moderate Alzheimer\u2019s Disease dementia. Clinical Nuclear Medicine (In press). 2025."},{"issue":"37","key":"2025050613201881000_2025.04.30.25326602v1.50","doi-asserted-by":"crossref","first-page":"e2309221120","DOI":"10.1073\/pnas.2309221120","article-title":"Nasal administration of anti-CD3 monoclonal antibody ameliorates disease in a mouse model of Alzheimer\u2019s disease","volume":"120","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025050613201881000_2025.04.30.25326602v1.51","doi-asserted-by":"crossref","unstructured":"Izzy S , Yahya T , Albastaki O , et al. Nasal anti-CD3 monoclonal antibody ameliorates traumatic brain injury, enhances microglial phagocytosis and reduces neuroinflammation via IL-10-dependent T(reg)-microglia crosstalk. Nat Neurosci. 2025 Feb 27.","DOI":"10.1038\/s41593-025-01877-7"},{"key":"2025050613201881000_2025.04.30.25326602v1.52","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaut.2016.10.001","article-title":"Mucosal administration of CD3-specific monoclonal antibody inhibits diabetes in NOD mice and in a preclinical mouse model transgenic for the CD3 epsilon chain","volume":"76","year":"2017","journal-title":"J Autoimmun."},{"key":"2025050613201881000_2025.04.30.25326602v1.53","first-page":"1","article-title":"Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis","volume":"360","year":"2019","journal-title":"Crohns Colitis"},{"key":"2025050613201881000_2025.04.30.25326602v1.54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.709861"},{"key":"2025050613201881000_2025.04.30.25326602v1.55","doi-asserted-by":"crossref","unstructured":"Sims EK , Bundy BN , Stier K , et al. Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals. Sci Transl Med. 2021 Mar 3;13(583).","DOI":"10.1126\/scitranslmed.abc8980"},{"key":"2025050613201881000_2025.04.30.25326602v1.56","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.9.3652"},{"key":"2025050613201881000_2025.04.30.25326602v1.57","doi-asserted-by":"crossref","unstructured":"Fox RJ , Bar-Or A , Traboulsee A , et al. Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis. N Engl J Med. 2025 Apr 8.","DOI":"10.1056\/NEJMoa2415988"},{"key":"2025050613201881000_2025.04.30.25326602v1.58","doi-asserted-by":"crossref","unstructured":"Oh J , Arnold DL , Cree BAC , et al. Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis. N Engl J Med. 2025 Apr 8.","DOI":"10.1056\/NEJMoa2415985"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.04.30.25326602","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:34:59Z","timestamp":1768509299000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.04.30.25326602"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,3]]},"references-count":58,"URL":"https:\/\/doi.org\/10.1101\/2025.04.30.25326602","relation":{},"subject":[],"published":{"date-parts":[[2025,5,3]]},"subtype":"preprint"}}